Ubivac To Present On Dark Genome-Derived Dark Matter/Proteome Cancer Immunotherapy At ...
Pioneering the World's 1st Dark Matter Cancer Immunotherapy UbiVac's DPV-001 is the World's 1st Dark Matter Cancer Immunotherapy in the Cli ...
DutchNews.nl6 小时
Thousands contract cancer on the job every year, experts say
Some 7,000 people a year are diagnosed with work-related cancers, research on behalf of cancer charity KWF Kankerbestrijding ...
Macau Business17 小时
Innovent and HUTCHMED Jointly Announce that the FRUSICA-2 Phase 2/3 Study of Sintilimab and ...
The combination of sintilimab and fruquintinib received conditional approval from China’s National Medical Products Administration (NMPA) for the treatment of patients with advanced endometrial cancer ...
BioSpace13 小时
GLP-1 Drug Boom Recalls the Rise of PD-1 Checkpoint Inhibitors
The explosion of GLP-1 weight loss drugs is reminiscent of the early days of PD-1 inhibitors, but key market differences ...